Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Tirza Areli Calderón Boyle"'
Autor:
Dana M. Chase, Soham Shukla, Julia Moore, Tirza Areli Calderón Boyle, Jonathan Lim, Jessica Perhanidis, Jean A. Hurteau, Jeanne M. Schilder
Publikováno v:
Oncology and Therapy, Vol 12, Iss 3, Pp 599-607 (2024)
Abstract Introduction Niraparib first-line maintenance (1LM) therapy has demonstrated clinical benefit for patients with ovarian cancer (OC) in clinical trial and real-world settings, but data on factors associated with real-world patient outcomes re
Externí odkaz:
https://doaj.org/article/877785eaaff34eb1860b79fe8e83b988
Autor:
Bobbie Rimel, Tirza Areli Calderón Boyle, Sara Burns, Jonathan Lim, John Hartman, Linda Kalilani, Jeanne M. Schilder, Jean A. Hurteau, Amanda Golembesky
Publikováno v:
Oncology and Therapy, Vol 12, Iss 3, Pp 465-475 (2024)
Abstract Introduction Clinical trials have demonstrated prolonged survival associated with niraparib first-line maintenance (1LM) therapy, compared with placebo, for patients with ovarian cancer (OC). However, data are limited on real-world 1LM nirap
Externí odkaz:
https://doaj.org/article/be7e5d732cdc4346b5c2c634f5e5b807
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Externí odkaz:
https://doaj.org/article/5239697fe8a94ac890ce1200c210b805
Autor:
Floor Backes, Tirza Areli Calderón Boyle, Jessica Perhanidis, Jonathan Lim, Linda Kalilani, Jean A Hurteau, Amanda Golembesky, Ritu Salani
Publikováno v:
Ovarian cancer.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5d7772b5d950f89d9c78a58df32690de
https://doi.org/10.1136/ijgc-2022-esgo.551
https://doi.org/10.1136/ijgc-2022-esgo.551
Autor:
Ritu Salani, Tirza Areli Calderón Boyle, Jessica Perhanidis, Jonathan Lim, Linda Kalilani, Jean A Hurteau, Amanda Golembesky, Floor Backes
Publikováno v:
Ovarian cancer.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5620e02850a21159b8d8dd74f47dbc85
https://doi.org/10.1136/ijgc-2022-esgo.527
https://doi.org/10.1136/ijgc-2022-esgo.527
Publikováno v:
Journal of Clinical Oncology. 39:e18695-e18695
e18695 Background: The treatment paradigm for advanced HR+/HER2- breast cancer has been rapidly evolving since the approval of the first CDK4/6 inhibitor in the U.S. in 2015. Available literature on real-world utilization of various treatment options
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c51a9df68379d27fca4b86e2032f04d7
https://doi.org/10.1200/jco.2021.39.15_suppl.e18695
https://doi.org/10.1200/jco.2021.39.15_suppl.e18695
Publikováno v:
Journal of Clinical Oncology. 38:e13600-e13600
e13600 Background: Adenoid cystic carcinoma (ACC) is a rare malignancy of the secretory glands, accounting for approximately 1% of head and neck cancers and 10% of salivary gland neoplasms. ACC primarily occurs in the major and minor salivary glands;
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::632245cde34e5b68d9e38e0084684808
https://doi.org/10.1200/jco.2020.38.15_suppl.e13600
https://doi.org/10.1200/jco.2020.38.15_suppl.e13600